Men on active surveillance for low- to intermediate-risk prostate cancer (PCa) have low risk for PCa-related mortality at a median follow-up of 18 years. However, a majority of men do progress and ...

Since the introduction of widespread PSA blood testing, many prostate cancers are now caught at an earlier, localized stage before they have spread. Catching cancer early hugely improves survival ...

A new population-level study from Uppsala University has found that most men treated for non-metastatic prostate cancer ...

Results of a study led by VHIO’s Prostate Cancer Group suggest that treatment with CDK4/6 inhibitors followed by senloytic ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

The study, published in JAMA Network Open, analyzed data from more than 5,000 U.S. veterans with metastatic prostate cancer who underwent next-generation sequencing between 2019 and 2023.

TAMPA, Fla. (May 16, 2025) — In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

For older patients with cancer and T2D, GLP-1 RA use is associated with lower all-cause mortality than DPP4i use.